Is Innospec Inc (IOSP) overvalued? · P/E 18, rev $1.78B
Innospec Inc (IOSP) is a specialty chemicals company listed on NASDAQ.
This page asks whether Innospec Inc (IOSP) looks expensive on cached numbers — not a short thesis.
Latest reported IOSP revenue for 2025-12-31 was $1.78B. Net income was $116.6M. Revenue was down 3.7% from 2024-12-31 to 2025-12-31. IOSP currently screens at market cap $2.05B and trailing P/E 18.1.
IOSP currently screens at market cap $2.05B and trailing P/E 18.1. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next IOSP 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the IOSP stock page for the full model, not this heading.
Not investment advice.